A Phase 4 interventional study of doxycycline monohydrate tablet and doxycycline carragenate tablet in Bacterial Infection, sponsored by Pfizer. Completed at 1 site in India. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-12-23.
Sponsored by Pfizer · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Bacterial Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Pfizer.
Among the 28 studies in Bacterial Infections by Pfizer, this one is the 17th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2008, is one of 5 in phase 4, and was the 21st registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →None of the 28 studies in Bacterial Infections by Pfizer is open now. The open studies under Bacterial Infections, anywhere →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 134 across the 21 interventional studies, 408 across the 6 observational. Of the 28 that completed or were terminated, 9 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Bacterial Infections by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: doxycycline monohydrate tablet
Drug: doxycycline carragenate tablet
Tablet, 100 mg, Single dose
Tablet, 100 mg, Single dose
Maximum Plasma Concentration (Cmax) of Doxycycline
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose.
Area Under Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) of Doxycycline
AUCinf = Area under the plasma concentration-time profile from time zero (pre-dose) to infinity.
Time frame: 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours postdose.
| Milestone | Doxycycline Monohydrate, Then Doxycycline Carragenate | Doxycycline Carragenate, Then Doxycycline Monohydrate |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| Milestone | Doxycycline Monohydrate, Then Doxycycline Carragenate | Doxycycline Carragenate, Then Doxycycline Monohydrate |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| ug/mL | Doxycycline Monohydrate | Doxycycline Carragenate |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Doxycycline | 2.526 ± 0.5090 | 2.442 ± 0.4585 |
AUCinf = Area under the plasma concentration-time profile from time zero (pre-dose) to infinity.
| ug*hr/mL | Doxycycline Monohydrate | Doxycycline Carragenate |
|---|---|---|
| Area Under Plasma Concentration-Time Profile From Time Zero to Infinity (AUCinf) of Doxycycline | 56.297 ± 10.3348 | 54.026 ± 11.4855 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Doxycycline Monohydrate | — | 0/24 (0%) | 1/24 (4.2%) |
| Doxycycline Carragenate | — | 0/24 (0%) | 2/24 (8.3%) |
| Event | Doxycycline Monohydrate | Doxycycline Carragenate |
|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 0/24 | 1/24 |
| ExcoriationInjury, poisoning and procedural complications | 0/24 | 1/24 |
| UrticariaSkin and subcutaneous tissue disorders | 1/24 | 0/24 |
| Age, Customized(participants) | Entire Study Population |
|---|---|
| < 18 years | 0 |
| 18 to 44 years | 24 |
| 45 to 64 years | 0 |
| > = 65 years | 0 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 0 |
| Male | 24 |
| Race/Ethnicity, Customized(participants) | Entire Study Population |
|---|---|
| Asian | 24 |
The record gives a start of Nov 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Doxycycline